US FDA emphasized in a recent warning to consumers that the number of adverse event reports on women with breast-implanted associated anaplastic large cell lymphoma (BIA-ALCL) worldwide has increased by about 246 reports, since last year.
FDA’s Device Center division of general surgery director Binita Ashar stated in the advisory that, as of September 2018,...






